Literature DB >> 19719797

Interactions of orexins/hypocretins with adrenocortical functions.

S M Kagerer1, O Jöhren.   

Abstract

The neuropeptides orexin A and B (hypocretin-1 and -2) are involved in numerous central regulation processes such as energy homeostasis, sleeping behaviour and addiction. The expression of orexins and orexin receptors in a variety of tissues outside the brain and the presence of orexin A in the circulation indicate the existence of an additional peripheral orexin system. Furthermore, it is well established that orexins exert an influence on the regulation of the hypothalamus-pituitary-adrenal axis, acting both on its central and peripheral branch. In rat and human adrenal cortices the expression of both orexin receptors has been verified with a predominance of OX(2)R. The local expression of orexin receptors was observed to be gender specific and to be modified by plasma glucose and insulin concentrations, nutritional status as well as gonadal steroids. Various studies consistently demonstrated orexin A to enhance glucocorticoid secretion of rat and human adrenal cortices, while orexin B was found to be either less potent or ineffective. On the contrary, the influence of orexins on adrenocortical aldosterone production and cell proliferation is still more controversial. Recent findings indicate that orexins stimulate adrenocortical steroidogenesis by augmenting transcription of selective steroidogenic enzymes and proteins such as steroidogenic acute regulatory protein. Both, G(q) and G(s), signalling pathways with a downstream activation of MAP kinases appear to be involved in this regulation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19719797     DOI: 10.1111/j.1748-1716.2009.02034.x

Source DB:  PubMed          Journal:  Acta Physiol (Oxf)        ISSN: 1748-1708            Impact factor:   6.311


  7 in total

1.  Orexin-1 receptor antagonism does not reduce the rewarding potency of cocaine in Swiss-Webster mice.

Authors:  Thorfinn T Riday; Eric W Fish; J Elliott Robinson; Thomas M Jarrett; Megan M McGuigan; C J Malanga
Journal:  Brain Res       Date:  2011-11-07       Impact factor: 3.252

2.  Orexins/hypocretins acting at Gi protein-coupled OX 2 receptors inhibit cyclic AMP synthesis in the primary neuronal cultures.

Authors:  Anna Urbańska; Paulina Sokołowska; Agata Woldan-Tambor; Kaja Biegańska; Britta Brix; Olaf Jöhren; Magdalena Namiecińska; Jolanta Barbara Zawilska
Journal:  J Mol Neurosci       Date:  2011-05-06       Impact factor: 3.444

3.  Hypothalamic orexin--a neurons are involved in the response of the brain stress system to morphine withdrawal.

Authors:  M Luisa Laorden; Szilamér Ferenczi; Bernadett Pintér-Kübler; Laura L González-Martín; M Carmen Lasheras; Krisztina J Kovács; M Victoria Milanés; Cristina Núñez
Journal:  PLoS One       Date:  2012-05-09       Impact factor: 3.240

4.  Dietary Manipulations That Induce Ketosis Activate the HPA Axis in Male Rats and Mice: A Potential Role for Fibroblast Growth Factor-21.

Authors:  Karen K Ryan; Amy E B Packard; Karlton R Larson; Jayna Stout; Sarah M Fourman; Abigail M K Thompson; Kristen Ludwick; Kirk M Habegger; Kerstin Stemmer; Nobuyuki Itoh; Diego Perez-Tilve; Matthias H Tschöp; Randy J Seeley; Yvonne M Ulrich-Lai
Journal:  Endocrinology       Date:  2018-01-01       Impact factor: 4.736

5.  Orexin A suppresses the growth of rat C6 glioma cells via a caspase-dependent mechanism.

Authors:  Kaja Biegańska; Paulina Sokołowska; Olaf Jöhren; Jolanta B Zawilska
Journal:  J Mol Neurosci       Date:  2012-05-17       Impact factor: 3.444

6.  The role of the glucocorticoids in developing resilience to stress and addiction.

Authors:  Subhashini Srinivasan; Masroor Shariff; Selena E Bartlett
Journal:  Front Psychiatry       Date:  2013-08-01       Impact factor: 4.157

Review 7.  Resilience to the effects of social stress on vulnerability to developing drug addiction.

Authors:  Claudia Calpe-López; Maria A Martínez-Caballero; Maria P García-Pardo; Maria A Aguilar
Journal:  World J Psychiatry       Date:  2022-01-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.